120 filings
Page 5 of 6
8-K
6sbxu87o0w 8fev1
15 Mar 18
Other Events
12:00am
8-K
88v5q
13 Mar 18
Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical Officer
12:00am
8-K
2f1 ztajxt1
7 Mar 18
Entry into a Material Definitive Agreement
12:00am
8-K
qi871p
7 Mar 18
Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update
12:00am
8-K
e8rvbzqz
8 Jan 18
Results of Operations and Financial Condition
12:00am
8-K
uj0hn
18 Dec 17
Entry into a Material Definitive Agreement
12:00am
8-K
hd6cnu42
7 Nov 17
Xenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
12:00am
8-K
8pu6wuuxxp8i 10
3 Aug 17
Xenon Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
12:00am
8-K
654gwr
27 Jun 17
Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint
12:00am
8-K
9b6dhe1ry0trmjl
2 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
8dy3d99
9 May 17
Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
12:00am
8-K
ajyiu1a3am
26 Apr 17
Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy
12:00am
8-K
wu066j08 0h
24 Mar 17
Other Events
12:00am
8-K
h7vk12bagsfih
14 Mar 17
Departure of Directors or Certain Officers
12:00am
8-K
cm9ywtugaa0
9 Mar 17
Other Events
12:00am
8-K
q7a3qdlyy6hbb
8 Mar 17
Xenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update
12:00am
8-K
xa9 zynidu2eqn
3 Jan 17
Other Events
12:00am
8-K
lodedgq0d6tsw091tj
3 Nov 16
Xenon Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update
12:00am
8-K
xcr689c64ejvm
27 Sep 16
Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Directors
12:00am
8-K
15txito lx
9 Sep 16
Other Events
12:00am